Malignant neoplasms occurring in the biliary tract and pancreas remain a therap- tic challenge. The mechanism of carcinogenesis as well as the growth and spread of these tumors is still poorly understood, making the development of rational tre- ment strategies difficult. In order to improve the clinical results achieved by sur- cal or other medical treatment of such malignant tumors, the establishment of an experimental animal model is critical. For this purpose, attempts were made to induce carcinoma experimentally in the biliary tree and finally an animal model using the hamster was established in 1994 at our laboratory. Because the tumor in this model mimicked the characteristics of human tumors, a series of experimental investigations were conducted to clarify the pathological characteristics of biliary carcinoma, the genetic alterations during biliary carcinogenesis, and the relationship between biliary inflammation and c- cinogenesis. The chemopreventive effects on the occurrence of biliary carcinoma were also successfully examined. In addition, in vitro studies led to the establi- ment of transplantable biliary cancer cell lines and biliary epithelial cell lines by utilizing the hamster model. This monograph represents the collective efforts in hepato-biliary and pancreatic disease research over the past 20 years. I hope that this monograph will be a source of useful knowledge for basic researchers as well as for clinicians involved in the care of patients with hepato-biliary and pancreatic neoplasms. Takashi Kanematsu, M.D., Ph.D.

This comprehensive, yet practical, text is a ready collection of the most up-to-date information on primary CNS tumors. Authored by a carefully selected group of the world's leading clinicians and scientists, the book is divided into three sections. The opening chapters cover general principles, including epidemiology, pathogenesis, tumor stem cells, supportive care, complications of therapy, and quality of life. The remaining two sections are comprised of treatment-oriented chapters covering the spectrum of gliomas and rarer tumor types. Each of these chapters presents multi-disciplinary therapeutic approaches and addresses specific disease concerns. Throughout, the authors incorporate the cutting-edge advances in molecular biology and genomics that are revolutionizing neuro-oncology. The result is an important clinical resource which provides evidence-based data and interpretation essential to intelligent therapeutic decision making.

Precis This book is a treatise about the origin of cancers. I would like to convince readers that the basic tenets of the theory of a stem-cell origin of cancers also constitute a unified theory of cancer. Stem-cell origin of normal (and cancer) cells: Vitruvian version Every truth passes through three stages before it is recognized. In the first it is ridiculed, in the second, it is opposed, in the third, it is regarded as self-evident. - Arthur Schopenhauer v vi Preface Every person has a unique story to tell. My story is about cancer. Cancer touches the lives of countless people. Often enough, it leaves indelible tracks. Many lives have been lost; others are forever changed. For those who confront this deadly scourge, there is a sense of urgency, if not of desperation. For those who face im- nent death, life becomes even more precious and carries a special meaning. As an oncologist, I am touched daily by cancer. I feel its inception, evolution, and aft- math. It seems as though we are fighting an incessant war against cancer at the front line in the trenches. This is my story about cancer. Some people are terrific storytellers. Others have incredible tales to tell.

Lung cancer and autoimmune diseases are complex entities in that they involve gene disturbance, gene polymorphism, and impaired gene repair mechanisms. The volume focuses on altered gene expression in tumor processes and in chronic autoimmune disorders. The chapters discuss the biological rationale for novel disease protein markers, present relevant clinical results, and give some diagnostic and therapeutic tips.

A link between inflammation and cancer has been established many years ago, yet it is only recently that the potential significance of this connection has become apparent. Although several examples of chronic inflammatory conditions, often induced by persistent irritation and/or infection, developing into cancer have been known for some time, there has been a notable resistance to contemplate the possibility that this association may apply in a causative way to other cancers. Examples for such progression from chronic inflammation to cancer are colon carcinoma developing with increased frequency in patients with ulcerative colitis, and the increased incidence of bladder cancer in patients suffering from chronic Schistosoma infection. Inflammation and cancer have been recognized to be linked in another context for many years, i.e., with regards to pathologies resembling chronic lacerations or 'wounds that do not heal.' More recently, the immunology of wound healing has given us clues as to the mechanistic link between inflammation and cancer, in as much as wounds and chronic inflammation turn off local cell-mediated immune responses and switch on growth factor release as well the growth of new blood vessels - angiogenesis. Both of these are features of most types of tumours, which suggest that tumours may require an immunologically shielded milieu and a growth factor-rich environment.

This volume explores the latest developments in a novel area of molecular biology and a hot topic in the field of oncology: cancer stem cells. These chapters from expert contributing authors present concepts such as the universal stem cell, new molecular pathways, new targeted agents, the different roles that cancer stem cells seem to have according to the organ they are placed in, and the future role that targeting cancer stem cells may have in the management of patients in the clinic.

Exploring the latest research including new data from randomized trials, this book examines important proposals over the origin of cancer stem cells such as the possibility that cancer stem cells may arise from mutated stem cells or a fully differentiated cell that may undergo several mutations that drive it back to a stem-like state. The authors consider the role that stem cells seem to have in the onset, development and resistance to classical antitumoral treatments of cancer and discuss possible potential future treatment modalities for the management of advanced cancer patients.

The question, "Are stem cells involved in cancer?" may not have a simple answer, but ongoing investigations, in-depth consideration and a broad spectrum of information can be found in this book, allowing the reader to arrive at his or her own answer.

This book will appeal to researchers in the field of oncology and cancer research and biomedical scientists with an interest in stem cells.

This volume discusses the latest advancements and technologies used in cancer drug resistance research. Cancer Drug Resistance: Overviews and Methods contains chapters that cover topics such as: studying the mechanics of resistance to DNA damaging therapeutic drugs; studies to delineate the role of efflux transporters; expression of drug transporters; resistance to targeted therapies in breast cancer; the role of microRNAs in current pancreatic cancer treatment; and cancer exosomes as mediators of drug resistance or clinical and molecular methods in drug development and the use of bioinformatics in the management of cancer drug resistance data. Written in the highly successful Methods in Molecular Biology series format, chapters include overviews of the main issues in cancer drug resistance and the respective mechanisms, as well as introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Cancer Drug Resistance: Overviews and Methods, is a valuable resource to researchers, oncobiologists and clinical oncologists or anyone else who is interested in the study of cancer and its drug resistances.

Having been a fairly dormant specialty for many decades, in recent years there has been a remarkable increase in activity in Neuro-oncology from basic science through to the clinics. Reflecting this there have been considerable advancements in the understanding of the biology of CNS malignancies which have infirmed the development of many novel and successful therapies. This work aims to bring together the scattered literature on the new concepts in neuro-oncology for the benefit of those in the field. The book moves from concepts in the scientific basis of neuro-oncology, through to modelling techniques and finishing on the translation into clinical practice.

This book provides a comprehensive and up-to-date review of the relationship between obesity and cancer. It opens with a global perspective on obesity and cancer incidence, followed by in-depth discussions of those cancers for which we have sufficient evidence of a causal relationship with obesity. It addresses topics such as the effects of obesity on cancer incidence and cancer survival, the effects of weight gain and weight loss in adulthood on cancer risk, the effects of childhood and adolescent obesity, and the role of body fat distribution in cancer risk. Individual chapters discuss potential pathways for the observed associations and explore possible mechanisms from both an epidemiological and an experimental perspective. It concludes with a population perspective on the cancer risk that is attributable to obesity and is thus potentially avoidable. This book is of particular value to researchers and epidemiologists and is also of interest to public health workers and clinicians.

approaches to the experimental problems that still face us in understanding this most fascinating of organs. Too many people contributed to the completion of this volume to allow acknowledg ment of all the individual efforts, but we particularly thank the reviewers whose input into the editorial process was invaluable and the authors of these chapters who revised their text, sometimes more than once, to bring it to the high standards set by the Editors. The Com mittee gratefully acknowledges the support ofVysis, Inc. , in the publication of a color figure in Chapter 19, by S. Weber-Hall and Trevor Dale. Finally, we wish to express our heartfelt appreciation to Margot Ip and Bonnie Asch, who worked long and hard to bring this volume to fruition. Margaret C. Neville for the Committee on Mammary Gland Biology Preface One of the most exciting and beneficial developments in research on mammary gland biology and breast cancer has been the influx of increased funding to support this work. This influx, which has been due primarily to the tireless efforts of breast cancer activists to gamer addi tional money from various federal and state sources, has led to a rapid expansion of research efforts by attracting numerous new investigators into the field. These new investigators include students, postdoctoral fellows, and scientists from other fields.

How to identify optimal phase II trial designs Providing a practical guide containing the information needed to make crucial decisions regarding phase II trial designs, A Practical Guide to Designing Phase II Trials in Oncology sets forth specific points for consideration between the statistician and clinician when designing a phase II trial, including issues such as how the treatment works, choice of outcome measure and randomization, and considering both academic and industry perspectives. A comprehensive and systematic library of available phase II trial designs is included, saving time otherwise spent considering multiple manuscripts, and real-life practical examples of using this approach to design phase II trials in cancer are given. A Practical Guide to Designing Phase II Trials in Oncology: * Offers a structured and practical approach to phase II trial design. * Considers trial design from both an academic and industry perspective. * Includes a structured library of available phase II trial designs. * Is relevant to both clinical and statistical researchers at all levels * Includes real life examples of applying this approach. * For those new to trial design, A Practical Guide to Designing Phase II Trials in Oncology will be a unique and practical learning tool, providing an introduction to the concepts behind informed decision making in phase II trials. For more experienced practitioners, the book will offer an overview of new, less familiar approaches to phase II trial design, providing alternative options to those which they may have previously used.

By detailing experimental and basic research, from premalignancy to fully invasive tumors, this book has wide applicability to all human carcinomas. No other group of human cancers is better positioned for the application of recently developed novel and targeted therapies, and this book uniquely presents the unusual opportunities tumors of the head and neck provide for clinical, translational, and basic science research. Cutting-edge and experimental treatment approaches are presented, along with future strategies and an evaluation of emerging technologies.
Key Features
* Presents a multi-disciplinary perspective from authorities in diverse fields
* Addresses state-of-the art approaches in cancer research as well as other scientific opportunities in this field
* Provides comprehensive yet easily comprehendible source of information

Electroporation is the forefront in tumor ablation. This book presents the basic principles and clinical applications of electroporation, including the latest research results and patient data. A comprehensive approach to the basic science behind the development of this ground-breaking technique and its introduction into clinical practice, the book discusses the entire spectrum of currently available reversible treatments, the emerging irreversible applications, and their impact on patient care. Clinical Aspects of Electroporation is the first book intended for clinicians on this extremely important and rapidly developing field.

Rectal Cancer: International Perspectives on Multimodality Management is a timely analysis of the diagnosis, staging, pathology, and therapy of cancer of the rectum. This book is intended as a useful resource for physicians, scientists, medical students, and allied health personnel in the disciplines of radiology, gastroenterology, surgical oncology, medical onc- ogy, radiation oncology, and pathology. Renowned contributors from different medical d- ciplines have written their chapters in a thoughtful, provocative, and visual fashion. Importantly, these chapters highlight the controversies in the diagnostic, staging, and the- peutic management of patients with rectal cancer while providing practical management recommendations. This book is divided into 18 chapters. Early chapters address the diagnosis and staging of rectal cancer, highlighting the critical role of contemporary imaging in guiding treatment. The remaining chapters focus on the multimodality management of rectal cancer from the vantage points of surgery, pathology, chemotherapy, and radiation therapy. The major dev- opments in surgery are reviewed first, including contemporary roles of local excision, total mesorectal excision, lateral pelvic lymph node dissection, organ preservation approaches, as well as the management of advanced, recurrent, and metastatic disease. Following is a ch- ter describing the pathologic evaluation of rectal cancer specimens, with emphasis on proper methodology and its clinical relevance to overall disease management. The final chapters review the contemporary roles of chemotherapy (including with radiation therapy, adjuvant and neoadjuvant settings without radiation therapy, as well as in metastatic disease) as well as radiation therapy (including adjuvant and neoadjuvant approaches, short vs.

The thoroughly updated and revised third edition of Management of Prostate Cancer provides concise and authoritative guidance to today's best therapeutic regimens for the diagnosis and treatment of prostate cancer. Highlighting the latest major advances in the field, the book includes chapters on the most controversial areas of prostate cancer - screening, chemoprevention, and active surveillance; updated chapters on genetic risk and progression, biopsy schemes, treatment of complications, and comparative treatment outcomes for surgery; and new chapters on risk factors, new markers, nomograms, and focal therapy. This volume also features overviews of new and emerging drugs and treatment paradigms for castrate resistant disease, advances that promise to extend life and perhaps even cure a subset of men with metastatic disease. With its comprehensive illustrations and contributions from renowned experts in the field, Management of Prostate Cancer, 3rd Edition is an invaluable resource for practitioners in the treatment of prostate cancer.

Myelodysplastic syndromes are to the bone marrow what pneumonia is to the lungs; the response of an organ to a variety of etiologic insults like aging, toxic exposure, infections and auto-immunity. Among infectious causes alone, pneumonia could be the result of a variety of possible pathogens including bacterial, viral, tuberculous or fungal agents. Similarly, MDS cannot be treated as a single disease. Attempts to harness the inherent complexity of MDS by devising classifications' which group the various syndromes as one disease is as misguided as saying that a pneumonia is not infectious because it did not respond to antibiotics. Progress in the field will occur faster when we re-analyze this premise. Therefore, until a clearer picture of the disease emerges it is best to treat each of the MDS syndromes as a separate entity. Having no classification is better than a misleading one. Cancer research has been notable for its periodic cycles of promise and hope, followed by defeat and disappointments. It is not that there is no solution, but that the problem has not been identified precisely. This book is our attempt to define the most crucial questions related to MDS that need to be addressed immediately through logic, analysis and rigorous experimentation. If the emerging problems appear daunting, then instead of being overwhelmed by them, we should follow the advice of the great 20th century thinker Antonio Gramsci, pessimism of the intellect must be faced with the optimism of will'.

Although there are numerous technical-scientific books on breast cancer in the global bibliography, such books deal exclusively with the nature of the disease in majority populations of the Western societies, with little or no reference to the nature of the disease in the minority populations in such societies. Similarly, the nature of breast cancer in black women of the less privileged societies, and in women of ethnic groups living in countries of similar socio-economic status, is virtually unknown. For various epidemiological reasons, breast cancer incidence is rapidly increasing in these counties, more so than currently is the case in developed countries. Thus, the global burden of cancer is shifting gradually to these areas of the world, and may equal or even surpass the breast cancer burden in the Western societies within the foreseeable future. This book is unique because it bucks the trend of virtually all other breast cancer books by addressing specifically the breast cancer experience of women of African descent and their lifestyle counterparts in other societies of the world.

This volume documents this unique family of cell surface proteins. Despite masquerading as intractable and difficult to clone and characterize, ENOX proteins have and continue to offer remarkable opportunities for research, commercial development and outside confirmation of therapeutic, diagnostic and new paradigms to help explain complex biological processes.

The Von Hippel-Lindau Tumor Suppressor Complex and Regulation of Hypoxia -Inducible Transcription. Retinoblastoma Tumor Suppressor and Genome Sta bility. The Abl Family Kinases: Mechanisms of Regulation an d Signaling. Cellular Immunity to the Her-2/neu Proto-oncog ene. A New Challenge for Successful Immunotherapy by Tumors That Are Resistant to Apoptosis: Two Complementary Signals to Overcome Cross-Resistance. Cell Volume and Ion Changes During Apopt otic Cell Death. Mitochondria and Apoptosis: New Therapeut ic Targets.

Coordinate Regulation of Translation by the PI 3-Kinase and mTOR Pathway s. Histone Acetyl-Transferases and Deacetylases in the Con trol of Cell Proliferation and Differentiation. Molecular Pathogenesis o f Human Hepatocellular Carcinoma. The Cell Mediated Immune Response to Human Papillomavirus Induced Cervical Cancer: Implications for Immunotherapy. The T-cell Response in Patients with Ca ncer. The Life and Death of a B Cell.

Recently the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development effective antagonists. One antagonist, plerixafor, is clinically approved now for stem cell mobilization of lymphoma and myeloma patients. This allows patients to receive potentially life-saving treatment which could not have been administered otherwise. Through early clinical studies it was recognized that CXCR4 antagonists also mobilize malignant hematopoetic cells, i.e. leukemia cells. In preclinical studies a sensitization of mobilized leukemic cells to standard cytotoxic chemotherapy could be shown. Clinical studies are under way. CXCR4 antagonists are an exciting new class of compounds which are also employed for the mobilization of angiogenic cells or for the treatment of solid tumors. In this book a concise review of the current status of knowledge and future developments will be presented.

This book provides a concise, yet comprehensive overview of the many facets relating to human health risk assessments in relation to chemical exposure problems. It presents some very important tools and methodologies that can be used to address chemical exposure and public health risk management problems in a consistent, efficient, and cost-effective manner. On the whole, the book represents a collection and synthesis of the principal elements of the risk assessment process that may be used to more effectively address issues pertaining to human exposures to chemicals found in modern societies. This also includes an elaboration of pertinent risk assessment concepts and techniques/methodologies for performing human health risk assessments. Written for both the novice and the experienced, the subject matter of this book is an attempt at offering a simplified and systematic presentation of public health risk assessment methods and application tools - all these facilitated by a layout that will carefully navigate the user through the major processes involved. A number of illustrative example problems are interspersed throughout the book, in order to help present the book in an easy-to-follow, pragmatic manner.

Chromosomes Today, Volume 13 includes the plenary lectures presented at the 13th International Chromosome Conference, covering the most recent advances in the studies on chromosomes. The contributions in this volume were presented by some of the world's leaders in cytogenetic and molecular research and outline the present status of knowledge on the composition, structure, function and evolution of chromosomes, including, among others, the advancement of the human genome project. The use of cytogenetic studies has greatly increased in the last few years, resulting in a progressive improvement in the available methods that has consequently allowed a more detailed analysis of the molecular organization of eukaryotic chromosomes and a precise in situ localisation of specific gene sequences. This volume of Chromosomes Today provides up-to-date information regarding the topics at the forefront of chromosome research: genetic regulation, imprinting, DNA duplication, meiotic pairing, and the regulation of the...